Sage View Advisory Group, LLC Intra Cellular Therapies, Inc. Transaction History
Sage View Advisory Group, LLC
- $2.32 Trillion
- Q4 2024
Shares
1 transactions
Others Institutions Holding ITCI
# of Institutions
419Shares Held
68.1MCall Options Held
934KPut Options Held
758K-
Vanguard Group Inc Valley Forge, PA9.52MShares$1.26 Billion0.02% of portfolio
-
Black Rock Inc. New York, NY6.32MShares$834 Million0.01% of portfolio
-
Ubs Oconnor LLC Chicago, IL3.09MShares$408 Million28.36% of portfolio
-
Farallon Capital Management LLC San Francisco, CA3.06MShares$403 Million2.32% of portfolio
-
Balyasny Asset Management LLC Chicago, IL2.26MShares$298 Million0.52% of portfolio
About Intra-Cellular Therapies, Inc.
- Ticker ITCI
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 94,401,696
- Market Cap $12.4B
- Description
- Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...